JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $45 price target The firm ...

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company’s shares closed yesterday at $7.16. Leverage the ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

09:46 EST SpringWorks Therapeutics (SWTX) trading halted, volatility trading pause Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a price target of $9.00. The company’s shares closed ...

Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top ...

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $7.19.

Both pedestrian hybrid beacons and rectangular rapid flashing beacons have been shown to reduce ... [+] pedestrian crashes, but in a new study, researchers compared behavior at the two different ...

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen, PSMA, claudin 18.2 and six-transmembrane ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $56.00. The company’s shares closed ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $7.19.

UBS initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $38 price target The firm says KIT inhibition is “differentiated in the underpenetrated” chronic spontaneous ...